JP2005533072A - 環置換されたジフェニルアゼチジノン、その製造方法、該化合物を含む医薬およびそれらの使用 - Google Patents

環置換されたジフェニルアゼチジノン、その製造方法、該化合物を含む医薬およびそれらの使用 Download PDF

Info

Publication number
JP2005533072A
JP2005533072A JP2004514660A JP2004514660A JP2005533072A JP 2005533072 A JP2005533072 A JP 2005533072A JP 2004514660 A JP2004514660 A JP 2004514660A JP 2004514660 A JP2004514660 A JP 2004514660A JP 2005533072 A JP2005533072 A JP 2005533072A
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
substituted
conh
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004514660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533072A5 (https=
Inventor
ゲーアハルト・イェーネ
ヴェンデリン・フリック
シュテファーニエ・フローア
アンドレーアス・リンデンシュミット
ハイナー・グロムビク
ヴェルナー・クラーマー
フーベルト・ホイアー
ハンス−ルートヴィヒ・シェーファー
Original Assignee
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2005533072A publication Critical patent/JP2005533072A/ja
Publication of JP2005533072A5 publication Critical patent/JP2005533072A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004514660A 2002-06-19 2003-06-04 環置換されたジフェニルアゼチジノン、その製造方法、該化合物を含む医薬およびそれらの使用 Abandoned JP2005533072A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10227506A DE10227506A1 (de) 2002-06-19 2002-06-19 Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP2003/005815 WO2004000804A1 (de) 2002-06-19 2003-06-04 Ringsubstituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number Publication Date
JP2005533072A true JP2005533072A (ja) 2005-11-04
JP2005533072A5 JP2005533072A5 (https=) 2006-07-13

Family

ID=29719281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004514660A Abandoned JP2005533072A (ja) 2002-06-19 2003-06-04 環置換されたジフェニルアゼチジノン、その製造方法、該化合物を含む医薬およびそれらの使用

Country Status (30)

Country Link
EP (1) EP1517892B1 (https=)
JP (1) JP2005533072A (https=)
CN (1) CN1662493A (https=)
AR (1) AR039689A1 (https=)
AT (1) ATE478842T1 (https=)
AU (1) AU2003242616B2 (https=)
BR (1) BR0311940A (https=)
CA (1) CA2490109A1 (https=)
DE (2) DE10227506A1 (https=)
EC (1) ECSP045498A (https=)
HN (1) HN2003000183A (https=)
HR (1) HRP20041203A2 (https=)
IL (1) IL165791A0 (https=)
MA (1) MA27252A1 (https=)
MX (1) MXPA04012236A (https=)
MY (1) MY135850A (https=)
NO (1) NO20050073L (https=)
NZ (1) NZ537304A (https=)
OA (1) OA12868A (https=)
PA (1) PA8576001A1 (https=)
PE (1) PE20040577A1 (https=)
PL (1) PL372690A1 (https=)
RS (1) RS108504A (https=)
RU (1) RU2315754C2 (https=)
SV (1) SV2004001549A (https=)
TN (1) TNSN04255A1 (https=)
TW (1) TW200404774A (https=)
UY (1) UY27851A1 (https=)
WO (1) WO2004000804A1 (https=)
ZA (1) ZA200409381B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7447226B2 (en) * 2003-10-31 2008-11-04 International Business Machines Corporation Methods and apparatus for continuous connectivity between mobile device and network using dynamic connection spreading
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
US8361999B2 (en) 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
DE602006010870D1 (de) 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2091915A1 (de) * 2006-11-02 2009-08-26 Sanofi-Aventis Deutschland GmbH Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
PT877750E (pt) * 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports

Also Published As

Publication number Publication date
HN2003000183A (es) 2003-08-01
BR0311940A (pt) 2005-04-05
NZ537304A (en) 2005-10-28
SV2004001549A (es) 2004-03-19
TW200404774A (en) 2004-04-01
OA12868A (en) 2006-09-15
ECSP045498A (es) 2005-03-10
TNSN04255A1 (en) 2007-03-12
UY27851A1 (es) 2003-12-31
AU2003242616B2 (en) 2008-12-11
MXPA04012236A (es) 2005-02-25
RU2315754C2 (ru) 2008-01-27
WO2004000804A1 (de) 2003-12-31
DE50313017D1 (de) 2010-10-07
ZA200409381B (en) 2006-05-31
DE10227506A1 (de) 2004-01-08
IL165791A0 (en) 2006-01-15
MY135850A (en) 2008-07-31
RS108504A (sr) 2007-02-05
EP1517892B1 (de) 2010-08-25
CN1662493A (zh) 2005-08-31
AU2003242616A1 (en) 2004-01-06
EP1517892A1 (de) 2005-03-30
NO20050073L (no) 2005-01-06
AR039689A1 (es) 2005-03-09
ATE478842T1 (de) 2010-09-15
CA2490109A1 (en) 2003-12-31
RU2005101091A (ru) 2005-07-10
MA27252A1 (fr) 2005-03-01
PE20040577A1 (es) 2004-10-11
PA8576001A1 (es) 2004-02-07
PL372690A1 (en) 2005-07-25
HRP20041203A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
JP2005533072A (ja) 環置換されたジフェニルアゼチジノン、その製造方法、該化合物を含む医薬およびそれらの使用
JP4605990B2 (ja) 新規な1,2−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
RU2287522C2 (ru) Замещенные кислотными группами дифенилазетидиноны, способ их получения, содержащие эти соединения лекарственные средства и их применение
RU2315753C2 (ru) Катионозамещенные дифенилазетидиноны, способ их получения, лекарственные средства, содержащие эти соединения, и их применение
US7579339B2 (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
KR20050016583A (ko) 환 치환된 디페닐 아제티디논, 이의 제조방법, 이를함유하는 약제 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060522

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20090811